Bide Pharmatech Co. Ltd. A

SHG:688073 China Drug Manufacturers - Specialty & Generic
Market Cap
$715.82 Million
CN¥5.25 Billion CNY
Market Cap Rank
#14817 Global
#3925 in China
Share Price
CN¥57.79
Change (1 day)
+2.27%
52-Week Range
CN¥37.81 - CN¥80.38
All Time High
CN¥105.19
About

Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.

Bide Pharmatech Co. Ltd. A - Asset Resilience Ratio

Latest as of June 2025: 18.22%

Bide Pharmatech Co. Ltd. A (688073) has an Asset Resilience Ratio of 18.22% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
CN¥460.90 Million
Cash + Short-term Investments
Total Assets
CN¥2.53 Billion
All company assets
Resilience Assessment
Good
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Bide Pharmatech Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Bide Pharmatech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥460.90 Million 18.22%
Total Liquid Assets CN¥460.90 Million 18.22%

Asset Resilience Insights

  • Good Liquidity Position: Bide Pharmatech Co. Ltd. A maintains a healthy 18.22% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Bide Pharmatech Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Bide Pharmatech Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
Drug Manufacturers - Specialty & Generic -0.02%
Kamada
NASDAQ:KMDA
Drug Manufacturers - Specialty & Generic 21.63%
Dongwha Pharm.Co.Ltd
KO:000020
Drug Manufacturers - Specialty & Generic 1.92%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
Drug Manufacturers - Specialty & Generic 0.46%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
Drug Manufacturers - Specialty & Generic 1.81%
Kotra Industries Bhd
KLSE:0002
Drug Manufacturers - Specialty & Generic 9.82%
Yuyu Pharma Inc
KO:000227
Drug Manufacturers - Specialty & Generic 1.74%

Annual Asset Resilience Ratio for Bide Pharmatech Co. Ltd. A (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Bide Pharmatech Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 3.12% CN¥75.52 Million CN¥2.42 Billion +3.12pp
2023-12-31 0.01% CN¥122.54K CN¥2.42 Billion -0.16pp
2022-12-31 0.17% CN¥3.97 Million CN¥2.36 Billion -7.92pp
2020-12-31 8.08% CN¥43.00 Million CN¥531.90 Million --
pp = percentage points